Why TELA Bio, Inc.’s (TELA) Stock Is Up 5.26%
As of Monday, October 05, TELA Bio, Inc.’s TELA share price has surged by 5.26%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Commentary & Analysis
Why TELA Bio, Inc.’s (TELA) Stock Is Down 5.60%
As of Friday, October 02, TELA Bio, Inc.’s TELA share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why TELA Bio, Inc.’s (TELA) Stock Is Down 5.16%
As of Monday, September 28, TELA Bio, Inc.’s TELA share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Michael Rose
Why TELA Bio, Inc.’s (TELA) Stock Is Up 5.38%
As of Thursday, September 24, TELA Bio, Inc.’s TELA share price has surged by 5.38%, which has investors questioning if this is right time to sell.Jenna Brashear
Why TELA Bio, Inc.’s (TELA) Stock Is Down 6.40%
As of Monday, September 21, TELA Bio, Inc.’s TELA share price has dipped by 6.40%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | TELA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $44.5 | $382.9 | 15% |
|
| Shares Out (Mil) | 57.4 | 40.9 | 51% |
|
| Institutional Ownership | 71.4% | 83.6% | 43% |
|
| Float (Mil) | 21.4 | 35.5 | 30% |
|
| Beta | 1.36 | 0.86 | 78% |
|
| Avg Daily Volume (000s) | 143 | 301 | 40% |
|
| Price Change (52-week) |
(33.5%) | 61.8% | 29% |
|
| Growth | TELA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 34.6% | 11.8% | 92% |
|
| Net Income (5yr) | (6.1%) | (5.5%) | 33% |
|
| EPS (5yr) | 18.0% | 10.6% | 65 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.5%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.155) | ($0.690) | ($0.450) | |
| Month Ago EPS | ($0.158) | ($0.694) | ($0.460) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.150) | ($0.668) | ($0.556) | |
| Year/Year Chg | (20.9%) | (16.6%) | (57.3%) | |
| Financials | TELA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $80 | $141 | 24% |
|
| Net Income (TTM) (Mil) | ($41) | ($9) | 18% |
|
| EPS (TTM) | ($0.778) | ($0.400) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($31) | ($2) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $1 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $57 | $27 | 40% |
|
| Enterprise Value (Q1) (Mil) | $61 | $418 | 17% |
|
| Valuation | TELA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.50 | na |
|
| P/E | na | 25.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | TELA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.3% | 58.7% | 80% |
|
| Net Margin | (51.5%) | (6.9%) | 11% |
|
| ROA | (64.7%) | (12.2%) | 9% |
|
| ROE | na | (10.7%) | na |
|
| Liabilities to Assets | 126.6% | 47.2% | 97% |
|
| F-Score | 3 | 4 | 18% |
|
TELA Bio, Inc. did not pass any screens on 10/16/2026.
